Clinical Study on MK-677
MK-677, also known as ibutamoren, has been the subject of several clinical studies to assess its effects on various aspects of human health. Here are some key findings from the available information:1. Effects on Body Composition and Clinical Outcomes: A two-year, randomized, double-blind, modified-crossover trial of once-daily oral administration of 25 mg MK-677 or placebo to healthy older adults was conducted. The study aimed to determine if MK-677, an oral ghrelin mimetic, would enhance growth hormone (GH) secretion in the elderly. The promise of MK-677 is that it appears to restore endogenous GH levels in a physiological secretory pattern, unlike the single high-amplitude pulse observed after exogenous GH administration
.2. Reversal of Diet-Induced Catabolism: A study investigated whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. The results indicated that MK-677 reverses diet-induced nitrogen wasting, suggesting potential usefulness in treating catabolic conditions. The study also reported that MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences
.3. Treatment of Growth Hormone Deficiency and Catabolic Conditions: MK-677 has been nominated as a treatment for growth hormone deficiency (GHD) and catabolic conditions. It has been extensively studied for its roles in promoting bone formation and resorption, aiding in fat loss, and improving sleep quality. However, it’s important to note that at the time of writing, there are no FDA-approved products containing ibutamoren mesylate, and MK-677 is classed as an Investigational New Drug in the United States, available to researchers as a reference material
.4. Effects on Bone Turnover in Elderly Adults: Chronic administration of MK-677 was studied to determine its effect on serum insulin-like growth factor I (IGF-I) and markers of bone turnover in healthy and functionally impaired elderly adults. The study enrolled 187 elderly adults and reported on the impact of MK-677 on serum IGF-I levels and markers of bone turnover
.5. Treatment for Sarcopenia in the Elderly: A systematic review elaborated on a clinical study that indicated MK-677’s potential in neutralizing factors contributing to the development of sarcopenia, such as reduced GH secretion, fat-free mass loss, and inadequate food intake. The review suggested that supplementation with MK-677 can significantly reduce these factors, safely and effectively, although more randomized clinical trials are needed to establish a consensus treatment
.In conclusion, the clinical studies on MK-677 have explored its potential effects on body composition, catabolism reversal, treatment of growth hormone deficiency and catabolic conditions, bone turnover in elderly adults, and its role in addressing sarcopenia in the elderly. It’s important to note that while these studies provide valuable insights, further research and clinical trials are necessary to fully understand the efficacy and safety of MK-677 for various health conditions.
Sources
